The potential of delivering a high and localized radiation dose using α‐particle‐emitting radioimmunoconjugates (RIC's) is investigated as treatment for some types of cancer. High specific activity of the RIC may for some uses be desirable, allowing enrichment of the radionuclide on membrane antigens on target cells. Radiation exposure during the radiolabelling procedures may, however, reduce the antigen binding ability of RIC's of high specific activity. The influence of α‐particle dose on the cell binding fraction was therefore investigated for two monoclonal antibodies, i.e., TP‐1 F(ab')2 and TP‐3 IgG. Samples of 125I‐labelled MoAb were added different amounts of [211At]astatide to give accumulated doses ranging from 50 to 50,000 Gy. After the 211At had decayed 15 half‐lives, the cell binding fractions were measured. The results show that [211At] astatide activities up to 25 kBq/μl, corresponding to an accumulated α‐particle radiation dose of approximately 1,000 Gy, could be tolerated without significantly reducing the cell binding fraction, whereas higher doses gradually reduced the immunoreactivity. Although there may be differences in dose sensitivity of different radioimmunoconjugate due to differences in radionuclide conjugation methods, size of the antibody and structure of the antigen binding portion, the results presented here indicate that it is possible to produce radioimmunoconjugates of high specific activity with currently used methods of preparation. The potential problem of radiolysis should, however, be taken into consideration when planning procedures for preparation and use of α‐particle‐emitting radioimmunoconjugates.